Breast imaging software developer Densitas has received an order for its Densitas densityai software for use in as many as 24 breast cancer screening clinics across Germany.
The software is designed to fully automate, standardize, and reproduce breast density assessments from standard DICOM clinical use mammograms. It can be used for breast density measurements at point of care to identify women for supplemental breast cancer screening as part of the DIMASOS 2 Trial.
The main objective is to determine whether combined mammography and ultrasound exams can improve early cancer detection and if this approach can be accomplished clinically and cost-effectively for routine screenings.
"The unique ability of the Densitas software to analyze prior 'for presentation' mammograms from a wide range of mammography scanner vendor models is pivotal to this trial and is important for any practical clinical deployment," noted Dr. Sylvia Heywang-Köbrunner, head of Referenzzentrum Mammographie München, in a statement.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
